Patent ID: 11944424
Assignee: DUKE UNIVERSITY
Field: Measurement (Instruments)
Classification: CPC A  G | IPC A  G

Claim 42:
43. A method of identifying whether a patient has one or more defined medical conditions using 129Xe spectral parameters, comprising:
obtaining a series of 129Xe free induction decays (FIDs) of a gas exchange region of a lung or lungs of a patient during a breathing maneuver;
fitting the FIDs in a time domain with a curve fitting function modeled with one or more non-Lorentzian line shapes, wherein the curve fitting function models each of a barrier resonance, a red blood cell (RBC) resonance and a gas-phase resonance;
electronically generating a plurality of static and dynamic 129Xe spectral parameters based on the fitting of a plurality of RBC spectral parameters comprising RBC amplitude, RBC chemical shift (ppm), RBC full width at half maximum (FWHM) (ppm), and RBC phase (degrees), wherein the dynamic 129Xe spectral parameters comprise oscillations of the plurality of the RBC spectral parameters as at least some of the dynamic 129Xe spectral parameters;
electronically evaluating one or more of a defined shape, pattern, peak size, and/or a frequency of the oscillations of at least two of the RBC amplitude, the RBC chemical shift (ppm), the RBC FWHM (ppm), and the RBC phase (degrees);
electronically calculating RBC transfer defect percentage, ventilation defect percentage, barrier defect percentage and high barrier uptake percentage using data from 129Xe Magnetic Resonance Imaging (MM) gas exchange images of the lung or lungs of the patient and
identifying whether the patient has one or more of the defined medical conditions based on the electronic evaluation,
wherein based at least in part on when peak-to-peak amplitude of the oscillations of the RBC amplitude is 7.9% or less, the patient is identified as likely having pre-capillary pulmonary hypertension, and
wherein based at least in part on when peak-to-peak amplitude of the oscillations of the RBC amplitude is greater than 10.2% and/or when high barrier uptake percentage is at or above 20%, the patient is identified as likely having Idiopathic pulmonary fibrosis (IPF).